Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genzyme MS Drug Gets Fast Track | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Genzyme MS Drug Gets Fast Track

MS Drug currently in two Phase III trials against Rebif

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme’s alemtuzumab treatment for multiple sclerosis has been granted Fast Track status by the FDA. This designation covers patients with relapsing-remitting forms of the disease.

The Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. It makes alemtuzumab for MS eligible for Priority Review and the FDA may consider for review portions of the marketing application before the NDA is completed.

“We are extremely pleased that our alemtuzumab development program has been assigned Fast Track status, and look forward to working closely with the FDA to expedite the program’s review process,” said Henri Termeer, Genzyme’s chairman and chief executive officer. “Alemtuzumab is a potentially transformative therapy for the treatment of multiple sclerosis, and an important part of our future.”

Alemtuzumab is currently being evaluated in two Phase III trials, comparing it to Rebif in early, relapsing-remitting multiple sclerosis (RRMS) patients who have received no prior therapy, and in RRMS patients who had active disease while on other MS therapies. Both trials are fully enrolled and data are expected to be available in 2011.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters